Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 3 (7), 2022-2044

Demethylating Agents in the Treatment of Cancer

Affiliations
Review

Demethylating Agents in the Treatment of Cancer

Paul M Howell et al. Pharmaceuticals (Basel).

Abstract

Gene silencing resulting from aberrant DNA methylation can lead to tumorigenesis. Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate and induce silenced gene re-expression in malignancies. Two demethylating agents, azacitidine and decitabine, are approved for the treatment of myelodysplastic syndromes (MDS) by the U.S. Food and Drug Administration (FDA), and are now considered the standard of care in MDS. In this review, we discuss clinical data, including clinical benefits and toxicities, which led to the approval of azacitidine and decitabine. We also summarize findings from clinical trials that used these two demethylating agents in the treatment of solid tumors. Lastly, we discuss some limitations in the use of azacitidine and decitabine in cancer therapy.

Keywords: azacitidine; cancer; decitabine; epigenetics; methylation.

Similar articles

See all similar articles

Cited by 12 PubMed Central articles

See all "Cited by" articles

References

    1. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. New Engl. J. Med. 2003;349:2042–2054. - PubMed
    1. Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer--a survey. Biochim. Biophys. Acta. 2007;1775:181–232. - PubMed
    1. McCabe M.T., Brandes J.C., Vertino P.M. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin. Cancer Res. 2009;15:3927–3937. - PMC - PubMed
    1. Tost J. Analysis of DNA methylation patterns for the early diagnosis, classification and therapy of human cancers. In: Kobayashi T.B., editor. DNA Methylation Research Trends. Nova Science Publishers; Hauppauge, NY, USA: 2007. pp. 87–133.
    1. Tost J. DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker. Mol. Biotechnol. 2010;44:71–81. - PubMed
Feedback